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Introductory note
The Key Issues of the 2020 European Drug Report (EDR), available in 24 languages, presents 
a selection of the main findings from the EMCDDA’s latest analysis of the drug situation in 
Europe, chosen for their policy relevance and general interest. A set of top-level tables from 
the EMCDDA annual Statistical Bulletin are also included here. 
The full version of this report, the 2020 EDR: Trends and Developments, is based on 
information provided to the EMCDDA by the EU Member States, the candidate country Turkey, 
and Norway, submitted through an annual reporting exercise. All groupings, aggregates and 
labels reflect the situation based on the available data in 2019 in respect to the composition 
of the European Union and the countries participating in EMCDDA reporting exercises 
in that year. Due to the time required for collation of data, annual data sets from national 
registries often reflect the reference year January to December 2018. Analysis of trends is 
based only on those countries providing sufficient data to describe changes over the period 
of interest. The reader should also be aware that monitoring patterns and trends in a hidden 
and stigmatised behaviour like drug use is both practically and methodologically challenging. 
Caution is therefore required in interpretation, in particular when countries are compared 
on any single measure. Detailed methodological information can be found in the online 
EMCDDA Statistical Bulletin which includes caveats and notes on the interpretation of data; 
qualifications on the analysis; and methodological information relating to the collection and 
interpretation of data and statistical information on the calculation of European and other 
averages, where interpolation may sometimes be used. 
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Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network 
is comprised of national focal points in the EU Member States, the candidate country 
Turkey, Norway and at the European Commission. Under the responsibility of their 
governments, the focal points are the national authorities providing drug information 
to the EMCDDA. The contact details of the national focal points may be found on the 
EMCDDA website.
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The analysis presented in this report is based on the most 
recent data available from routine monitoring and describes 
the drug situation in Europe at the end of 2019. Since 
then, European countries have been greatly affected by 
the outbreak and rapid spread of the coronavirus disease 
2019 (COVID-19) pandemic. The enforcement of restrictive 
public health measures necessary to curb transmission of 
the virus have impacted all areas of life including drug use, 
drug markets and the implementation of law enforcement 
and health and social responses to the drug phenomenon. 
Across Europe, 2020 has seen, to varying degrees, the 
introduction of restrictive measures unprecedented in 
peacetime, including closure of non-essential services, 
border closures, limitations on the right to assembly and 
freedom of movement. This situation has had an immediate 
impact on many behaviours linked to drug use and drug 
supply, as well as disrupting health provision and some 
law enforcement activities. Subsequently, the relaxing or 
lifting of some of the public health measures has created 
the conditions for a rebound towards the pre-COVID-19 
situation. However, at the time of writing, the situation 
remains volatile and the pandemic continues to have an 
impact across many key policy areas, including drugs. 
Importantly, COVID-19 still poses a major threat to global 
health and security and is likely to do so for some time. The 
pandemic is also likely to have, in the medium to long term, 
an economic and social impact that will have wide-ranging 
implications, including some for the future problems we are 
likely to face in the drugs area.
From the start of the pandemic, the EMCDDA has been 
committed to supporting its stakeholders in responding to 
the immediate challenges in this area. The agency analysed 
the special needs and risks for people who use drugs, in 
order to prevent coronavirus infections among this group. 
We have also considered how drug services could adapt 
to mitigate the impact of the pandemic on their clients 
and staff. The EMCDDA has been closely following the 
development of the situation and responses to it, acting 
as a conduit for information-sharing. In a series of rapid 
studies, we have also reported on the impact of COVID-19 
on drug use and associated problems, help-seeking, service 
provision and the operation of the drug market. The situation 
requires regular review and our ongoing work on it can be 
accessed from our COVID-19 web area.
Looking to the future, three important questions remain to 
be answered. Will we see a return to the situation as it was 
at the end of 2019 and, if so, how quickly will this happen? 
In addition, will there be important medium and long-term 
implications for drug use and the future drug problems we 
face, or for how services respond to problems in this area? 
And finally, what lessons can be learnt from the pandemic 
in order to increase the resilience of our policy responses in 
this area if faced by future crises? The data reported here 
provide a valuable baseline for these considerations, and 
the EMCDDA is committed to following these issues closely. 
COVID-19 PANDEMIC AND 
THE DRUG SITUATION
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For the complete set of data and information on the methodology, see the accompanying online Statistical Bulletin.
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KEY ISSUE | Large drug shipments are increasingly intercepted
Many indicators for the most commonly used substances suggest drug  
availability remains high. Alongside developments in production, an increase  
in the interception of large quantities of cocaine, cannabis resin and increasingly 
heroin transported by sea often in intermodal containers raises concerns around  
the infiltration by organised crime groups of logistical supply chains, shipping  
routes and large ports. 
MAIN EDR 2020 FINDINGS 
  Around 1.3 million seizures were reported in 2018 
in Europe, with cannabis products most often seized 
(Figure 1).
  In 2018 the quantity of cannabis resin seized 
in the European Union rose to 668 tonnes 
from 468 tonnes in 2017 (Figure 2). A number 
of countries that generally seize small quantities 
of herbal cannabis showed considerable increases 
in 2018. One example is Belgium, where the 
17.3 tonnes seized was 18 times the amount 
seized in the previous year. 
  The quantity of cocaine seized in the European Union 
reached the highest levels ever recorded in 2018, 
amounting to 181 tonnes (138 tonnes in 2017). 
  In 2018 the amount of heroin seized in the European 
Union increased to 9.7 tonnes, up from 5.2 tonnes 
in 2017, mainly due to large individual seizures made 
in the port of Antwerp. In 2017 and 2018 Turkey 
seized around 17 tonnes of heroin each year (17.4 and 
17.8 tonnes), the largest quantities for a decade.
EUROPE’S DRUG  
SITUATION UP TO 2020:
KEY ISSUES IDENTIFIED
940 % 29 % 10 %
6 %
6 %
5 %
2 %
3 %
Herbal cannabis Cannabis resin
Cannabis resin
Cocaine
Herbal cannabis
Heroin
Cannabis 
plants
Cocaine 
and crack
Amphetamines
Other 
substances
Heroin
MDMA
NUMBER OF REPORTED DRUG SEIZURES, BREAKDOWN BY DRUG, 2018
FIGURE 1
FIGURE 2
TRENDS IN QUANTITIES OF CANNABIS, COCAINE AND HEROIN SEIZED IN THE EUROPEAN UNION 
tonnes
tonnes
tonnes
tonnes
2012
2012
2012
2012
2008
2008
2008
2008
2013
2013
2013
2013
2009
2009
2009
2009
2014
2014
2014
2014
2010
2010
2010
2010
2015
2015
2015
2015
2011
2011
2011
2011
2016
2016
2016
2016
2017
2017
2017
2017
2018
2018
2018
2018
0
0
0
0
500
100
150
7.5
1000
200
300
15
Europe’s drug situation up to 2020
10
European Drug Report 2020: Key issues
KEY ISSUE | Cocaine’s role in Europe’s drug problem is increasing
The number and quantity of cocaine seizures are now the highest ever reported, with 
over 181 tonnes of the drug seized in 2018. Belgium, Spain and the Netherlands are 
key countries for the interception of large quantities. Indicators point to high availability 
of cocaine on the European market and signs of growth in countries where it was 
previously uncommon. Crack cocaine use, while still uncommon, is now reported by 
more countries. The purity of cocaine at retail level has increased almost every year 
since 2009, and in 2018 it reached the highest level in the last decade. Collectively, 
the high purity of the drug, along with data from treatment services, emergency 
presentations and drug-induced deaths, suggest that cocaine is now playing a more 
important role in the European drug problem. The cocaine market also appears an 
important driver for drug-related violence. 
MAIN EDR 2020 FINDINGS 
  Belgium (53 tonnes), Spain (48 tonnes) and the 
Netherlands (40 tonnes) together accounted for 78 % 
of the estimated 181 tonnes of cocaine seized in the 
European Union in 2018.
  The average purity of cocaine at retail level varied from 
23 % to 87 % across Europe in 2018, with half the 
countries reporting an average purity between 53 % 
and 69 %. Overall, cocaine purity in Europe has been 
on an upward trend over the past decade, while the 
retail price of cocaine has remained stable. 
  Of the 12 countries that have conducted surveys 
among young adults (15-34) since 2017 and reported 
confidence intervals, 5 reported higher estimates of 
last year use compared with their previous survey and 
7 had stable estimates.
  Of the 45 cities that have data from analysis of 
municipal wastewater for cocaine residues for 2018 
and 2019, 27 reported an increase, 10 a stable 
situation, and 8 a decrease. Increasing longer-term 
trends are observable for most of the 14 cities with 
data covering the 2011 to 2019 period. 
  The number of cocaine first-time treatment entrants 
increased in 22 countries between 2014 and 2018, 
and 17 countries reported an increase in the last year.
  Most treatment entrants citing cocaine as their main 
problem drug are powder cocaine users (56 000 clients 
in 2018). There were 15 000 crack-related treatment 
demands reported in 2018. 
  Cocaine was the second most common drug involved 
in presentations monitored by Euro-DEN Plus in 2018.
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Apart from trends, data are for all treatment entrants with cocaine as primary drug. Trends in first-time entrants are based on 24 countries. Only countries with data 
for at least 11 of the 13 years are included in the trends graph. Missing values are interpolated from adjacent years. Due to changes in the flow of data at national 
level, data since 2014 for Italy are not comparable with earlier years. United Kingdom data for 2018 do not include Northern Ireland. 
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KEY ISSUE | The potential for increased heroin use and existing 
harms raise concerns 
Indicators of heroin use continue to suggest an ageing cohort of users with low rates 
of initiation. In addition, new drug treatment entries associated with heroin have 
also fallen in many countries. However, a doubling of the volumes of heroin seized 
within the European Union and increasing volumes seized in Turkey are worrying, 
as are reports of heroin manufacturing taking place within the European Union. This 
suggests more vigilance is necessary to detect any signs of increased consumer 
interest in a drug associated with serious health and social problems. 
MAIN EDR 2020 FINDINGS
  The prevalence of high-risk opioid use among adults 
(15-64) is estimated at 0.4 % of the EU population, 
equivalent to 1.3 million high-risk opioid users in 2018. 
  In 2018 primary heroin users accounted for 77 % 
(almost 20 000 clients) of first-time primary opioid 
users entering treatment, a drop of 2 200 clients or 
10 % compared with the previous year. 
  The number of first-time heroin clients has fallen 
by more than half from a peak observed in 2007. 
Between 2017 and 2018, the number of first-time 
treatment entrants for primary heroin use decreased in 
18 countries out of the 29 with available data.
  Opioids, mainly heroin or its metabolites, often in 
combination with other substances, are present in the 
majority of fatal overdoses reported in Europe. 
  After cannabis and cocaine, heroin was the third 
most common substance involved in drug-related 
acute toxicity presentations monitored by Euro-DEN 
Plus in 2018.
  In 2018 half the countries reported a mean purity of 
heroin at retail level in the range 18-30 % and a mean 
price in the range EUR 29-79 per gram. Both purity 
and price of the drug have stabilised in recent years, 
albeit with purity at a relatively high level. Seizures of 
heroin in the European Union, however, are increasing 
(see page 9).
 Indicators of heroin use  
 continue to suggest an ageing  
 cohort of users with low  
 rates of initiation 
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with earlier years. United Kingdom data for 2018 do not include Northern Ireland. 
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KEY ISSUE | Understanding the public health impact of  
high-potency cannabis and new products 
Cannabis now plays a major role in drug treatment admissions, but the relationship 
between cannabis problems and developments in the drug market remains poorly 
understood. This is at a time when the cannabis market is changing, with the 
presence of high-THC (tetrahydrocannabinol) content products, and new forms 
of cannabis and commercial products based on extracts from the cannabis plant 
becoming increasingly available. Moreover, cannabis resin and herb now contain 
on average about twice as much THC as they did just a decade ago. Taken together 
this suggests that there is a pressing need for greater surveillance in this area. These 
issues and others like the availability of low-THC products marketed for their high 
CBD (cannabidiol) content are examined in a forthcoming edition of EMCDDA’s 
Cannabis: controversies and challenges series of briefings.
MAIN EDR 2020 FINDINGS
  Analysis of indexed trends shows an overall increase 
in the potency of both herbal cannabis and cannabis 
resin since 2008. The latest data suggest that the 
THC content of resin sold in Europe is now on average 
almost twice that of herbal cannabis.
  Of the countries that have produced surveys since 
2017 and reported confidence intervals, 8 reported 
higher estimates of last year cannabis use among 
young adults (15-34), 3 were stable and 1 reported 
a decrease compared with the previous comparable 
survey. In 8 of these countries, an increase in use 
among 15- to 24-year-olds has been reported in the 
most recent survey.
  From surveys of the general population, it is estimated 
that around 1 % of adults in the European Union are 
daily or almost daily cannabis users — that is, they 
have used the drug on 20 days or more in the last 
month. The majority of these (60 %) are under 35 and 
around three quarters are male. 
  In 2018 around 135 000 people entered specialised drug 
treatment in Europe for problems related to cannabis 
use (32 % of all treatment demands); of those, about 
80 000 were entering treatment for the first time. 
  In the 24 countries with available data, the overall 
number of first-time entrants for cannabis problems 
increased by 64 % between 2006 and 2018. Fifteen 
countries reported an increase between 2006 and 
2018 and 14 reported an increase in the last year 
(2017-2018). 
  Overall, 50 % of primary cannabis users entering 
treatment for the first time in 2018 reported daily use 
of the drug in the last month.
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KEY ISSUE | Increased and diverse drug production within Europe 
Established and new drugs continue to be produced in Europe, for local and global 
markets, with more laboratories and production sites detected by law enforcement. 
Changes in the production tactics of organised crime groups are part of the reason 
behind this trend, but also access to cheaper and novel precursor chemicals and 
processing equipment. The production of illicit drugs is now based on a more 
diverse set of chemicals, which are both difficult to respond to under European 
and international laws and challenging to monitor. 
MAIN EDR 2020 FINDINGS
  Cannabis: There were 3.3 million cannabis plants 
seized in the European Union in 2018, an indicator 
of the production of the drug within a country. 
  Heroin: In 2018 almost 16 tonnes of the heroin 
precursor chemical acetic anhydride was seized in the 
European Union and the supply of a further 9 tonnes 
was stopped before it entered the supply chain.
  The discovery of laboratories producing heroin 
from morphine in Bulgaria, Czechia, Spain and the 
Netherlands in recent years, together with an increase 
in morphine and opium seizures suggests some 
heroin is now manufactured in the European Union. 
  Cocaine: Small but increasing seizures of coca leaves 
have also been observed (243 kilograms in 2018) as 
have small seizures of coca paste (184 kilograms), 
indicating the use of laboratories manufacturing 
cocaine from coca leaves or paste. 
  Amphetamine: The total quantities of precursors 
and alternative chemicals used for the production of 
amphetamine seized in 2018 in the European Union 
reached an all-time high at 73 tonnes. Seizures of the 
alternative chemical APAA have increased sharply in 
the last few years, tripling to over 30 tonnes in 2018 
compared with 2017.
  Methamphetamine seized in Europe is mainly 
produced in Czechia, from pseudoephedrine extracted 
from medicinal products, and the border areas of 
neighbouring countries. 
  MDMA: Twenty-three active MDMA laboratories were 
reported to have been dismantled in the European 
Union in 2018, with most (20) detected in the 
Netherlands. The discovery of 2 MDMA laboratories 
in Spain and 1 in Sweden suggest a diversification of 
production locations may be under way.
  The seized quantities of the MDMA precursor PMK 
(piperonyl methyl ketone) and non-scheduled 
chemicals for MDMA manufacture have decreased 
from 26 tonnes in 2017 to under 16 tonnes in 2018. 
  New psychoactive substances: In 2018, a total of 
50 kilograms of the cathinone precursor 2-bromo-4-
methylpropiophenone was seized within the European 
Union, while 3 laboratories were detected producing 
mephedrone (Spain, Netherlands, Poland), indicating 
the continued production of this drug within Europe.
  In 2018 more than half a kilogram of 4-anilino-N-
phenethylpiperidine (ANPP) was seized in France 
and a shipment of 3 kilograms of N-phenethyl-4-
piperidone (NPP) was stopped in Belgium. Both 
are precursors for the manufacture of fentanyl 
and fentanyl derivatives.
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Drug type What is Europe’s role in 
production?
Focus of control measures in 
Europe on the production and 
movement of drugs
What are the main challenges for law 
enforcement? 
Cannabis resin Mostly imported; some 
resin production in 
Europe
Supply chain Varying of smuggling routes and methods
Smuggling through unstable territories
Use of various maritime vessels (e.g. speedboats), 
civil aviation and unmanned aircraft
Herbal cannabis Produced in Europe for 
European markets
Cultivation sites
Supply chain
Localised and dispersed cultivation sites near 
consumer markets to minimise detection risks
Retail-level sales on darknet drug markets
Distribution though postal, parcel and delivery 
systems
Cocaine Imported; limited 
production in Europe
Supply chain
Precursor control
Processing facilities such as 
base-to-HCl and secondary 
extraction labs 
Continued use of controlled precursors in 
production
Varying of smuggling routes and methods
Use of container transport
Corruption of port and other authorities
Heroin Imported; limited 
production in Europe; 
source of precursors
Supply chain
Precursor control
Production facilities
Continued use of controlled precursors in 
production
Varying of smuggling routes and methods
Use of container transport
Amphetamine Produced in Europe for 
European and to a limited 
extent Middle Eastern 
markets
Precursor control
Production facilities, including 
waste dumping sites
Supply chain
Use of novel chemicals in manufacturing
Signs of localised processing and production 
Methamphetamine Produced in Europe for 
European markets
Precursor control
Production facilities, including 
waste dumping sites
Supply chain
Continued use of controlled precursors in 
production 
Use of novel chemicals in manufacturing
Increasing role of organised crime
MDMA Produced in Europe for 
European and global 
markets
Precursor control
Production facilities, including 
waste dumping sites
Supply chain
Continued use of controlled precursors in 
production
Use of novel chemicals in manufacturing
Retail level sales on darknet drug markets
Distribution though postal, parcel and delivery 
systems
New psychoactive 
substances
Chemicals mainly 
imported; some 
production in Europe; 
processing in Europe
Supply chain
Production facilities
Detection of production sites
Diverse unscheduled production materials 
 Established and new drugs  
 continue to be produced  
 in Europe, for local and  
 global markets, with more  
 laboratories and production  
 sites detected by law  
 enforcement 
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KEY ISSUE | Continuing availability of high-strength MDMA 
products highlights need for greater user awareness 
Innovation and scaling-up of synthetic drug production in Europe is evident in 
the continued availability of high-content MDMA tablets and high-purity powders. 
Alongside increases in both the average MDMA content in tablets and the purity 
of powders in 2018, data show that products containing extremely high levels of 
MDMA are also being detected. These products pose considerable health risks for 
people using them and raise an important issue for prevention and harm reduction 
messaging and interventions.
MAIN EDR 2020 FINDINGS
  On average, MDMA tablets now contain higher levels 
of the drug than at any time in the past. Trend analysis 
shows that the average content of MDMA tablets has 
been stable at high levels since 2014, though due to 
lack of data this analysis is only possible up to 2017. 
  Among the 12 countries that have provided new survey 
results since 2017 and reported confidence intervals, 
4 reported higher estimates than in the previous 
comparable survey, and 8 reported stable estimates.
  Of the 42 cities that have data for 2018 and 2019, 
23 reported an increase, 4 a stable situation and 
15 a decrease.
  MDMA was the sixth most common drug recorded in 
emergency presentations monitored by Euro-DEN Plus 
in sentinel hospitals in 2018 (Figure 3) and accounted 
for 8 % of drug-related admissions to critical care.
  An estimated 4.7 million MDMA tablets were reported 
seized in 2018, down from 6.6 million in 2017. 
  Seizures of MDMA powder in the European Union 
increased from 1.7 tonnes in 2017 to 2.2 tonnes 
in 2018. 
  Large quantities of MDMA tablets were seized 
in Turkey in 2017 and 2018, amounting in both  
years to more than 8 million tablets, and exceeding  
the total amount seized in the European Union.
 Innovation and scaling-up  
 of synthetic drug production  
 in Europe is evident in the  
 continued availability of  
 high-content MDMA tablets  
 and high-purity powders 
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KEY ISSUE | Growing complexity in the drug market poses 
regulatory challenges and health risks 
A better understanding of the availability of both uncontrolled and less common 
substances, and their impact on public health, is clearly needed. These substances are 
often poorly monitored, but there is evidence to suggest they may constitute a growing 
problem, as indicated for example by the increased quantities seized of ketamine, GHB 
(gamma-hydroxybutyrate) and LSD (lysergic acid diethylamide). In addition, concerns 
have been raised by some countries about the use of substances like nitrous oxide 
(N2O, laughing gas). Non-controlled and new benzodiazepines, obtained online or 
through the more conventional illicit drug market, are also a growing concern. Etizolam, 
for example, which is not an authorised medicine in most countries, appears to be 
commonly available on drug markets in some countries and has been linked to increases 
in drug-induced deaths among people who use opioids.
MAIN EDR 2020 FINDINGS
  In 2018, 15 EU countries reported around 
1 900 seizures of ketamine, amounting to an 
estimated 328 kilograms and 12 litres of the drug.
  An estimated 1 500 seizures of GHB or GBL  
(gamma-butyrolactone) were reported in 2018 by 
13 EU countries, amounting to almost 3.3 tonnes 
and 1 732 litres. 
  National estimates, where they exist, of the prevalence 
of ketamine and GHB use in adult and school 
populations appear low. 
  Over 2 400 seizures of LSD were reported in 2018, 
amounting to 1.06 million units. Most of these (93 %) 
were seized in Spain. The overall number of LSD 
seizures has more than doubled since 2010, although 
the quantity seized has fluctuated. 
  Among young adults (15-34), most national surveys 
report last year prevalence estimates equal to or less 
than 1 % for both LSD and hallucinogenic mushrooms 
in 2018 or most recent survey year.
  The EU Early Warning System is monitoring 30 new 
benzodiazepines — 21 of which were first detected 
in Europe since 2015 (Figure 4). In 2018 close 
to 4 700 seizures of new benzodiazepines were 
reported to the EU Early Warning System, amounting 
to 1.4 million tablets, 1.3 litres of liquids and under 
8 kilograms of powders. 
  Etizolam, monitored by the EU Early Warning System 
since 2011, and, more recently, flualprazolam, 
first detected in 2018, have been associated with 
poisonings and deaths in some countries.
FIGURE 4
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KEY ISSUE | New tools and innovative strategies are needed 
to support the scaling-up of hepatitis C treatment 
Drug injection remains a major route for hepatitis C virus (HCV) infections in Europe, and 
access of people who inject drugs to prevention, testing and treatment for hepatitis C is 
therefore a critical requirement for the elimination of this disease. While effective oral 
direct-acting antiviral medications are now more available, scaling up the provision of 
these medicines, together with opioid substitution treatment and needle exchange 
programmes, remains a challenge for many countries. The introduction of improved 
diagnostic and surveillance techniques to identify those chronically infected with this 
virus is important for the targeting of treatment to all those infected. 
MAIN EDR 2020 FINDINGS
  Viral hepatitis, particularly infection caused by the 
hepatitis C virus, is highly prevalent among injecting 
drug users across Europe.
  In 2017-18, HCV antibody prevalence in national 
samples of people who inject drugs varied from 16 % 
to 86 %, with 10 of the 16 countries with national data 
reporting rates in excess of 50 % (Figure 5). 
  It is important to identify individuals who remain 
chronically infected: they are at risk of cirrhosis and 
cancer, and can transmit the virus to others when 
sharing any injecting material that has been in contact 
with their blood. 
Countries with 
national data
HCV ANTIBODY PREVALENCE AMONG PEOPLE WHO INJECT DRUGS: SEROPREVALENCE STUDIES AND DIAGNOSTIC TEST RESULTS 
WITH NATIONAL AND SUBNATIONAL COVERAGE, 2017-18
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KEY ISSUE | Drug overdose is increasingly associated with 
an ageing population 
Between 2012 and 2018 the number of drug overdose deaths among the 50-plus age 
group increased by 75 %, indicating that this problem is increasingly associated with 
older long-term users. This underlines the need to recognise the increasing vulnerability 
of an ageing cohort of life-long drug users and make this group an important target for 
treatment, social reintegration and harm reduction measures. 
MAIN EDR 2020 FINDINGS
  It is estimated that at least 8 300 overdose deaths 
involving illicit drugs occurred in the European Union 
in 2018, representing a stable situation compared with 
2017. This total rises to an estimated 9 200 deaths if 
Norway and Turkey are included, representing a slight 
decrease in relation to the revised estimate of 9 500 in 
2017. The European analysis, however, is provisional 
and probably understates the actual number of deaths 
that occurred in 2018.
  Opioids, mainly heroin or its metabolites, often in 
combination with other substances, are present in the 
majority of fatal overdoses reported in Europe.
  Three quarters (76 %) of those dying from overdose 
are male. The mean age of those who died in Europe 
continued to increase, reaching 41.7 years in 2018. 
  Between 2012 and 2018, overdose deaths in the 
European Union increased in all age categories with 
the exception of those aged 20-29. Increases were 
particularly marked among the 50-plus age groups, 
where the number of deaths rose by 75 % overall. 
Analysis of fatal overdoses reported by Turkey in 2018 
shows a younger profile than the European Union 
average, with a mean age of 32.5 years (Figure 6).
  The mortality rate due to overdoses in Europe in 2018 is 
estimated at 22.3 deaths per million population aged 
15-64. Males aged 35 to 44 are the most affected, 
with a mortality rate of 53.7 deaths per million, more 
than double the average seen for all ages, and more 
than three times the highest mortality rate in females 
(13.9 deaths per million females aged 35-44 years). 
 Between 2012 and 2018  
 the number of drug overdose  
 deaths among the 50-plus  
 age group increased by 75 %,  
 indicating that this problem is  
 increasingly associated with  
 older long-term users 
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DRUG-INDUCED DEATHS
Data refer to EU Member States, Turkey and Norway (EU + 2).
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KEY ISSUE | New psychoactive substances have become  
a more persistent problem 
The pace at which new psychoactive substances are being introduced onto the 
market has stabilised in recent years. Nonetheless, more than 50 new psychoactive 
substances continue to be detected for the first time annually by the EU Early 
Warning System. Alongside this, each year about 400 previously reported new 
psychoactive substances are detected on the European market. These substances 
are drawn from a broad range of drug types and are not controlled by international 
drug laws. They include stimulants, synthetic cannabinoids, benzodiazepines, opioids, 
hallucinogens and dissociatives.
MAIN EDR 2020 FINDINGS
  At the end of 2019, the EMCDDA was monitoring 
around 790 new psychoactive substances, 53 of 
which were reported for the first time in Europe in 
2019 (Figure 7). 
  Since 2015 approximately 400 previously reported 
new psychoactive substances have been detected 
each year (Figure 8).
  During 2018 law enforcement agencies from across 
Europe reported close to 64 800 seizures of new 
psychoactive substances to the EU Early Warning 
System. Of these, approximately 40 200 seizures were 
reported by the EU Member States, a slight decrease 
compared with 2017.
  In 2018 more than 5.6 tonnes of new psychoactive 
substances, mostly in the form of powders, was 
reported to the EU Early Warning System, 4.4 tonnes 
of which by Member States. In addition, 4 212 litres of 
liquids and 1.6 million tablets and capsules were also 
found to contain new psychoactive substances. 
  In Europe, seizures of new psychoactive substances 
are typically dominated by synthetic cannabinoids 
and cathinones, which together accounted for 77 % 
of all seizures reported in 2018 (64 % for the EU 
Member States).
  Surveys of the general population, where available, 
suggest low levels of use of new psychoactive 
substances in European countries.
  New psychoactive substances represented 5 % 
of all drugs submitted for testing by individuals 
to a network of drug checking services operating 
in 11 European countries during the first half of 
2019. It should be noted that these results are 
not representative of the market as a whole.
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NUMBER AND CATEGORIES OF NEW PSYCHOACTIVE SUBSTANCES REPORTED TO THE EU EARLY WARNING SYSTEM  
FOR THE FIRST TIME, 2008-19
NUMBER AND CATEGORIES OF SUBSTANCES DETECTED EACH YEAR, FOLLOWING THEIR FIRST DETECTION, 2008-18 
FIGURE 7
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KEY ISSUE | Appearance of new synthetic opioids is a worrying 
example of continuing market adaptability 
Growing awareness about the individual and public health risks associated with 
fentanyl derivatives has resulted in actions that include increased restrictions in 
producer countries. One sign of the market adapting may be that of the 8 new 
synthetic opioids detected for the first time in 2019 by the EU Early Warning System, 
6 were not fentanyl derivatives, though potentially presenting a similar threat to 
public health.
MAIN EDR 2020 FINDINGS
  Since 2009 a total of 57 new synthetic opioids have 
been detected on Europe’s drug market – including 
8 reported for the first time in 2019 (Figure 9). 
  In contrast to recent years, only 2 of these 
opioids were fentanyl derivatives. The remaining 
6 opioids (2-fluoro-viminol, AP-237, 2-methyl-
AP-237, piperidylthiambutene, furanyl UF-17 and 
isotonitazene) are all chemically different from 
fentanyl, despite posing similar concerns in respect 
to their toxicity.
  In 2018 approximately 1 000 seizures of new opioids 
were reported to the EU Early Warning System. This 
amounted to approximately 9.3 kilograms of material, 
of which just under 7.3 kilograms was in the form 
of powders. Additionally, 5.4 litres of liquids and 
21  500 tablets and capsules (excluding tramadol) 
were also reported. 
NUMBER OF NEW SYNTHETIC OPIOIDS REPORTED TO THE EU 
EARLY WARNING SYSTEM FOR THE FIRST TIME, 2008-19
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Annex
National data for estimates of drug use prevalence including problem 
opioid use, substitution treatment, total number in treatment, treatment 
entry, injecting drug use, drug-induced deaths, drug-related infectious 
diseases, syringe distribution and seizures. The data are drawn from and 
are a subset of the EMCDDA Statistical Bulletin 2020, where notes and 
meta-data are available. The years to which data refer are indicated.
ANNEX
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OPIOIDS
TABLE A1
Country
Problem opioid use 
estimate
Entrants into treatment during the year
Clients in 
substitution 
treatment
Opioids clients as % of treatment 
entrants
% opioids clients injecting 
(main route of administration)
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
Year of 
estimate
cases 
per 
1 000
% (count) % (count) % (count) % (count) % (count) % (count) count
Belgium – – 21.1 
(2 322)
6.6 (269) 30.4 
(1 969)
13.7 (287) 11.4 (28) 13.8 (245) 16 179
Bulgaria – – 83.1 (987) 52.2 (144) 91.7 (705) 74.2 (710) 67.7 (88) 73.8 (516) 3 181
Czechia 2018 1.5-1.6 17.2 (751) 9.9 (188) 22.9 (525) 61.8 (443) 60.2 (112) 62.4 (311) 5 000
Denmark 2016 4.0-9.6 11 (565) 6.3 (151) 15.6 (404) 15 (85) 2.6 (4) 19.8 (80) 6 600
Germany 2016-17 2.4-3.1 17.3 
(6 977)
8.5 (1 972) – 22.3 
(1 067)
17.6 (246) – 79 400
Estonia – – 93.4 (271) 87.4 (76) 95.5 (150) 69.3 (187) 72 (54) 80.7 (121) 1 052
Ireland 2014 6.1-7.0 42.2 
(4 178)
18.1 (718) 60.2 
(3 312)
29.7 
(1 202)
19.7 (141) 32.2 
(1 032)
10 332
Greece 2018 1.6-2.4 55.1 
(2 036)
32.5 (494) 70.2 
(1 485)
26.5 (526) 19.5 (95) 29.1 (424) 9 162
Spain 2017 1.5-3.1 24.9 
(11 632)
12 (2 850) 39.4 
(8 404)
15.8 
(1 816)
8.4 (240) 17.5 
(1 457)
59 857
France 2017 4.5-5.9 24.8 
(11 935)
11.4 
(1 509)
39.7 
(7 519)
17.4 
(1 774)
10.2 (139) 20 (1 304) 178 665
Croatia 2015 2.5-4.0 – 21.2 (203) – – 30.9 (56) – 4 792
Italy 2018 6.5-7.2 42.6 
(16 445)
26.4 
(4 256)
54.1 
(12 189)
45.9 
(6 252)
32 (1 050) 50.4 
(5 202)
75 711
Cyprus 2018 1.6-2.7 24.4 (272) 13.3 (72) 38.6 (187) 36.3 (94) 44.1 (30) 34.1 (61) 257
Latvia 2017 4.7-7.0 49.4 (399) 28.7 (123) 72.8 (276) 82.8 (323) 73.8 (90) 86.9 (233) 690
Lithuania 2016 2.7-6.5 82.4 
(1 075)
50.7 (105) 89.1 (961) 83.3 (895) 77.1 (81) 84 (807) 1 275
Luxembourg 2015 4.5 51.6 (158) 35.4 (29) 59.6 (115) 46 (64) 34.8 (8) 48.5 (50) 1 142
Hungary 2010-11 0.4-0.5 2.6 (121) 1.2 (43) 6.7 (63) 34.7 (35) 7.9 (3) 52.6 (30) 650
Malta 2017 4.2-4.9 56.3 
(1 067)
19.5 (76) 65.8 (991) 54.2 (578) 30.3 (23) 56 (555) 729
Netherlands 
(1)
2012 1.1-1.5 11.5 
(1 262)
6.2 (402) 19.3 (860) 6.1 (39) 7.6 (13) 5.6 (26) 5 241
Austria 2017 6.1-6.5 47.5 
(1 966)
29.8 (548) 61.6 
(1 418)
34.7 (553) 21.1 (90) 39.6 (463) 19 216
Poland 2014 0.4-0.7 15.7 
(1 035)
6.2 (201) 25.7 (822) 53.5 (545) 36.7 (73) 58 (469) 2 797
Portugal 2015 3.8-7.6 37.1 
(1 214)
20.8 (379) 57.7 (835) 11 (127) 5.8 (21) 13.4 (106) 17 246
Romania 2017 0.8-2.9 24.6 
(1 048)
10.8 (314) 54 (734) 83.4 (859) 80.8 (253) 84.5 (606) 1 772
Slovenia 2018 3.1-4.3 79.5 (174) 44.9 (22) 89.3 (151) 39.1 (68) 13.6 (3) 42.4 (64) 3 301
Slovakia 2018 0.6-1.6 26.5 (805) 9.3 (115) 39.6 (676) 71.4 (566) 66.1 (74) 72.7 (487) 620
Finland 2017 6.9-8.6 48.5 (328) 35.5 (86) 55.8 (242) 77.3 (252) 75.6 (65) 77.9 (187) 3 329
Sweden (2) – – 23.6 
(10 005)
16.1 
(2 259)
27.7 
(7 363)
– – – 4 014
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Country
Problem opioid use 
estimate
Entrants into treatment during the year
Clients in 
substitution 
treatment
Opioids clients as % of treatment 
entrants
% opioids clients injecting 
(main route of administration)
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
Year of 
estimate
cases 
per 
1 000
% (count) % (count) % (count) % (count) % (count) % (count) count
United 
Kingdom (3)
2014-15 8.3-8.7 49.7 
(55 687)
21.9 
(7 502)
62.1 
(48 081)
30.7 
(11 553)
15.6 (646) 32.7 
(10 884)
147 568
Turkey 2011 0.2-0.5 63 (7 141) 47.2 
(2 446)
76.3 
(4 695)
24.1 
(1 719)
14.1 (346) 29.2 
(1 373)
12 500
Norway (4) 2013 2.0-4.1 17 (1 010) 11.4 (309) 21.6 (701) – – – 7 762
European 
Union
– – 33.1 
(134 715)
15.4 
(25 106)
48.7 
(100 437)
31.6 
(30 960)
21.5 
(3 726)
34.6 
(25 720)
659 778
EU, Turkey 
and Norway
– – 33.7 
(142 866)
16.3 
(27 861)
49.1 
(105 833)
31.1 
(32 619)
20.6 
(4 072)
34.3 
(27 093)
680 040
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.
Data on clients in substitution treatment are for 2018 or most recent year available: Luxembourg, 2017; Croatia, Denmark, France, Slovakia and Spain, 2016; 
Netherlands and Finland, 2015; Turkey, 2011. The number for Sweden does not represent all clients.
(1) Data for the number of clients in substitution treatment is not complete.
(2)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative  
of the national picture. 
(3)  The high-risk opioid use estimate and the entrants into treatment data do not include Northern Ireland. Clients in substitution treatment relates  
to England and Wales.
(4) The percentage of clients in treatment for opioid-related problems is a minimum value, not accounting for opioid clients registered as polydrug users.
Annex | National data tables 
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COCAINE
TABLE A2
 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Cocaine clients as % of treatment entrants
% cocaine clients injecting 
(main route of administration)
Lifetime, 
adults  
(15-64)  
%
Last 12 
months, 
 young adults 
(15-34)  
%
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All clients First-time entrants
Previously 
treated 
entrants
% (count) % (count) % (count) % (count) % (count) % (count)
Belgium 2018 – 2.9 25.4 
(2 804)
25.3 
(1 037)
24.7 
(1 600)
3.8 (97) 1.1 (11) 5.4 (77)
Bulgaria 2016 0.9 0.5 3.5 (41) 7.6 (21) 2.6 (20) 0 (0) 0 (0) 0 (0)
Czechia 2018 1.3 0.2 0.9 (38) 1 (19) 0.8 (18) 10.8 (4) 10.5 (2) 11.1 (2)
Denmark 2017 6.4 3.9 18.9 (971) 21.3 (511) 16.7 (432) 1.7 (16) 0.2 (1) 3.6 (15)
Germany 2018 4.1 2.4 6.5 (2 598) 6.6 (1 533) – 2 (36) 1.7 (18) –
Estonia 2018 5.0 2.8 0.3 (1) 1.1 (1) – – – –
Ireland 2015 7.8 2.9 22.1 
(2 186)
31.1 
(1 231)
15.9 (878) 0.8 (17) 0.5 (6) 1 (9)
Greece 2015 1.3 0.6 11.6 (429) 15.3 (233) 9.2 (194) 8.5 (36) 3.1 (7) 15 (29)
Spain 2017 10.3 2.8 43.1 
(20 168)
43.8 
(10 393)
42.3 
(9 025)
0.9 (179) 0.3 (36) 1.5 (138)
France 2017 5.6 3.2 10.8 
(5 182)
9.8 (1 300) 12.5 
(2 368)
8.2 (382) 2.7 (33) 12.2 (264)
Croatia 2015 2.7 1.6 – 3.2 (31) – – 3.2 (1) –
Italy 2017 6.9 1.7 32.7 
(12 641)
37.3 
(6 014)
29.4 
(6 627)
2.6 (294) 1.5 (79) 3.6 (215)
Cyprus 2016 1.4 0.4 17.8 (199) 15.9 (86) 20.2 (98) 2.6 (5) 2.4 (2) 3.1 (3)
Latvia 2015 1.5 1.2 0.5 (4) 0.7 (3) 0.3 (1) 0 (0) 0 (0) 0 (0)
Lithuania 2016 0.7 0.3 1.1 (15) 3.4 (7) 0.6 (7) 6.7 (1) 0 (0) 14.3 (1)
Luxembourg 2014 2.5 0.6 20.6 (63) 23.2 (19) 17.6 (34) 51.9 (27) 38.9 (7) 58.3 (14)
Hungary 2015 1.2 0.9 3 (143) 3.2 (113) 2.7 (25) 2.2 (3) 2.7 (3) 0 (0)
Malta 2013 0.5 – 26.8 (508) 49 (191) 21 (317) 16.5 (84) 3.7 (7) 24.3 (77)
Netherlands 2018 6.5 3.9 24.3 
(2 675)
20.8 
(1 357)
29.6 
(1 318)
0.4 (5) 0.1 (1) 0.6 (4)
Austria 2015 3.0 0.4 10.7 (443) 11.4 (210) 10.1 (233) 9.5 (41) 3.9 (8) 14.5 (33)
Poland 2018 0.7 0.5 2.6 (173) 2.2 (72) 3.1 (99) 1.2 (2) 1.4 (1) 1.1 (1)
Portugal 2016 1.2 0.3 19.9 (650) 21.8 (397) 17.5 (253) 2.4 (15) 1 (4) 4.6 (11)
Romania 2016 0.7 0.2 1.5 (64) 1.9 (55) 0.7 (9) 1.6 (1) 0 (0) 11.1 (1)
Slovenia 2018 2.7 1.8 7.3 (16) 18.4 (9) 4.1 (7) 25 (4) 0 (0) 57.1 (4)
Slovakia 2015 0.7 0.3 0.9 (28) 1.5 (18) 0.5 (9) – – –
Finland 2018 3.2 1.5 0.4 (3) 0.8 (2) 0.2 (1) 0 (0) 0 (0) 0 (0)
Sweden (1) 2017 – 2.5 1.7 (715) 3 (424) 0.7 (190) – – –
United 
Kingdom (2) 
2018 10.1 5.3 19.4 
(21 750)
25.4 
(8 712)
16.8 
(12 981)
1.7 (257) 0.4 (24) 2.7 (226)
Turkey 2017 0.2 0.1 2.9 (328) 3.2 (166) 2.6 (162) 0 (0) – 0 (0)
Norway 2018 5.1 2.3 1.9 (112) 2.8 (75) 1.1 (37) – – –
31
 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Cocaine clients as % of treatment entrants
% cocaine clients injecting 
(main route of administration)
Lifetime, 
adults  
(15-64)  
%
Last 12 
months, 
 young adults 
(15-34)  
%
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All clients First-time entrants
Previously 
treated 
entrants
% (count) % (count) % (count) % (count) % (count) % (count)
European 
Union
– 5.4 2.4 18.3 
(74 508)
20.9 
(33 999)
17.8 
(36 744)
2.4 
(1 506)
0.9 (251) 3.7 
(1 124)
EU, Turkey 
and Norway
– – – 17.7 
(74 948)
20 
(34 240)
17.1 
(36 943)
2.4 
(1 506)
0.9 (251) 3.7 
(1 124)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France,  
Germany, Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden.
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.
(1)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative  
of the national picture. 
(2) Entrants into treatment do not include Northern Ireland.
Annex | National data tables 
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AMPHETAMINES
TABLE A3
 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Amphetamines clients as % of treatment entrants
% amphetamines clients injecting 
(main route of administration)
Lifetime, 
adults 
(15-64)
Last 12 
months, 
young 
adults 
(15-34)
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
%  
(count)
% 
(count)
%  
(count)
%  
(count)
%  
(count)
% 
(count)
% 
 (count)
% 
(count)
Belgium 2018 – 0.8 9.2 
(1 015)
7 (285) 10.9 (706) 14.6 
(125)
10.1 (24) 16.4 (100)
Bulgaria 2016 1.5 1.8 7.1 (84) 20.3 (56) 3.3 (25) 1.2 (1) 0 (0) 0 (0)
Czechia 2018 2 0.5 50.1 
(2 185)
53.8 
(1 018)
46.9 
(1 074)
62.5 
(1 315)
57 (569) 68 (707)
Denmark 2017 7.0 1.4 6.1 (312) 5 (121) 7.1 (183) 3 (9) 2.5 (3) 3.5 (6)
Germany 2018 4.1 2.9 16.2 
(6 511)
14.5 
(3 387)
– 1.9 (79) 1.5 (33) –
Estonia 2018 6.1 2.1 3.8 (11) 6.9 (6) 2.5 (4) 50 (5) 66.7 (4) 33.3 (1)
Ireland 2015 4.1 0.6 0.6 (56) 0.9 (34) 0.3 (18) 7.4 (4) 5.9 (2) 11.1 (2)
Greece – – – 1.1 (41) 1.1 (16) 1.2 (25) 12.2 (5) 6.2 (1) 16 (4)
Spain 2017 4 0.9 1.5 (689) 1.7 (410) 1.2 (252) 1.2 (8) 1.5 (6) 0.8 (2)
France 2017 2.2 0.6 0.5 (220) 0.4 (50) 0.4 (80) 11.6 (20) 18.6 (8) 4.2 (3)
Croatia 2015 3.5 2.3 – 3.4 (33) – – 0 (0) –
Italy 2017 2.4 0.3 0.3 (102) 0.4 (67) 0.2 (35) 4.5 (4) 5.1 (3) 3.4 (1)
Cyprus 2016 0.5 0.1 6.6 (74) 5.7 (31) 8.5 (41) 7 (5) 10 (3) 5 (2)
Latvia 2015 1.9 0.7 17.5 
(141)
22.9 (98) 11.3 (43) 64.1 (84) 54.9 (50) 85 (34)
Lithuania 2016 1.2 0.5 2.8 (36) 9.2 (19) 1.3 (14) 16.7 (6) 15.8 (3) 21.4 (3)
Luxembourg 2014 1.6 0.1 0.3 (1) – – – – –
Hungary 2015 1.7 1.4 11.4 
(538)
11.2 
(394)
13 (122) 5.5 (29) 3.1 (12) 12.4 (15)
Malta 2013 0.3 – 0.3 (6) – 0.4 (6) 50 (3) – 50 (3)
Netherlands 2018 5.6 2.7 7.4 (817) 7.5 (487) 7.4 (330) 1.3 (4) 1 (2) 1.9 (2)
Austria 2015 2.2 0.9 5.6 (232) 7.1 (131) 4.4 (101) 1.4 (3) 0.8 (1) 2.1 (2)
Poland 2018 2.4 1.4 30.4 
(1 998)
33 
(1 074)
27.7 (885) 2.3 (45) 1.3 (14) 3.5 (30)
Portugal 2016 0.4 0.0 0.2 (5) 0.2 (3) 0.1 (2) 20 (1) 33.3 (1) 0 (0)
Romania 2016 0.3 0.1 0.5 (23) 0.7 (19) 0.3 (4) 0 (0) 0 (0) 0 (0)
Slovenia 2018 2.3 1.1 0.9 (2) 0 (0) 1.2 (2) 50 (1) 0 (0) 50 (1)
Slovakia 2015 1.4 0.8 40.8 
(1 241)
48.9 
(602)
34.8 (594) 28.1 
(331)
26.8 
(158)
30.5 (170)
Finland 2018 4.7 3.0 20.3 
(137)
17.8 (43) 21.7 (94) 73.5 
(100)
54.8 (23) 81.9 (77)
Sweden (1) 2017 – 1.2 6.6 
(2 778)
7.5 
(1 055)
4.8 (1 278) – – –
United Kingdom (2) 2018 8.6 1.0 2.1 
(2 305)
2.6 (880) 1.8 (1 416) 17.6 
(262)
11.1 (60) 21.4 (201)
Turkey 2017 0.0 – 7.8 (886) 12.2 
(631)
4.1 (255) 0.1 (1) – 0.4 (1)
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 Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Amphetamines clients as % of treatment entrants
% amphetamines clients injecting 
(main route of administration)
Lifetime, 
adults 
(15-64)
Last 12 
months, 
young 
adults 
(15-34)
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
All 
entrants
First-time 
entrants
Previously 
treated 
entrants
%  
(count)
% 
(count)
%  
(count)
%  
(count)
%  
(count)
% 
(count)
% 
 (count)
% 
(count)
Norway 2018 3.5 0.9 12.9 
(770)
10.3 
(280)
15.1 (490) – – –
European Union – 3.7 1.2 5.3 
(21 560)
6.3 
(10 319)
3.6 (7 334) 17.2 
(2 449)
13.3 
(980)
26.6 
(1 366)
EU, Turkey and 
Norway
– – – 5.5 
(23 216)
6.6 
(11 230)
3.7 (8 079) 16.2 
(2 450)
12.3 
(980)
25.4 
(1 367)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France,  
Germany and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden. 
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.  
Data for Germany, Sweden and Norway refer to users of ‘stimulants other than cocaine’.
(1)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative  
of the national picture. 
(2) Entrants into treatment do not include Northern Ireland.
Annex | National data tables 
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MDMA
TABLE A4
Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population MDMA clients as % of treatment entrants
Lifetime, adults 
(15-64)
Last 12 months, 
young adults 
(15-34)
All entrants First-time entrants
Previously 
treated entrants
% % % (count)  % (count) % (count)
Belgium 2018 – 2.5 0.6 (62) 1 (43) 0.2 (16)
Bulgaria 2016 2.1 3.1 0.2 (2) 0.7 (2) 0 (0)
Czechia 2018 5.3 1.6 0.7 (30) 0.7 (14) 0.7 (15)
Denmark 2017 3.2 1.5 – – –
Germany 2018 3.9 2.8 – – –
Estonia 2018 5.4 2.5 0.3 (1) – 0.6 (1)
Ireland 2015 9.2 4.4 0.3 (32) 0.5 (18) 0.2 (12)
Greece 2015 0.6 0.4 0.2 (6) 0.3 (4) 0.1 (2)
Spain 2017 3.6 1.2 0.1 (68) 0.2 (56) 0 (10)
France 2017 3.9 1.3 0.3 (168) 0.5 (62) 0.2 (46)
Croatia 2015 3.0 1.4 – 0.8 (8) –
Italy 2017 2.7 0.8 0.1 (56) 0.1 (24) 0.1 (32)
Cyprus 2016 1.1 0.3 0.2 (2) 0.2 (1) 0.2 (1)
Latvia 2015 2.4 0.8 0.4 (3) 0.2 (1) 0.5 (2)
Lithuania 2016 1.7 1.0 0.5 (6) 1 (2) 0.4 (4)
Luxembourg 2014 1.9 0.4 0.3 (1) – 0.5 (1)
Hungary 2015 4.0 2.1 2.3 (110) 2.1 (75) 3.3 (31)
Malta 2013 0.7 – 0.9 (17) – 1.1 (17)
Netherlands 2018 10.3 6.9 0.7 (80) 1 (67) 0.3 (13)
Austria 2015 2.9 1.1 1 (42) 1.3 (24) 0.8 (18)
Poland 2018 1.0 0.5 0.3 (23) 0.6 (18) 0.2 (5)
Portugal 2016 0.7 0.2 0.2 (7) 0.3 (6) 0.1 (1)
Romania 2016 0.5 0.2 1.3 (55) 1.8 (52) 0.2 (3)
Slovenia 2018 2.9 1.3 0.5 (1) 2 (1) 0 (0)
Slovakia 2015 3.1 1.2 0.4 (13) 0.6 (8) 0.2 (4)
Finland 2018 5.0 2.6 0 (0) 0 (0) 0 (0)
Sweden 2017 – 2.0 – – –
United Kingdom (1) 2018 9.1 3.1 0.5 (555) 1.2 (396) 0.2 (156)
Turkey 2017 0.4 0.2 1.5 (172) 2.3 (118) 0.9 (54)
Norway 2018 3.6 1.7 – – –
European Union – 4.1 1.9 0.3 (1 340) 0.5 (882) 0.2 (390)
EU, Turkey and Norway – – – 0.4 (1 512) 0.6 (1 000) 0.2 (444)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France,  
Germany, Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, United Kingdom and Norway; 18-65 for Malta; 17-34 for Sweden. 
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.
(1) Entrants into treatment do not include Northern Ireland.
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TABLE A5
Country Year of survey
Prevalence estimates Entrants into treatment during the year
General population Cannabis clients as % of treatment entrants
Lifetime, adults 
(15-64)
Last 12 months, 
young adults 
(15-34)
All entrants First-time entrants
Previously 
treated entrants
% % % (count) % (count) % (count)
Belgium 2018 22.6 13.6 34.6 (3 808) 51 (2 090) 24.4 (1 579)
Bulgaria 2016 8.3 10.3 2.2 (26) 4.3 (12) 1.7 (13)
Czechia 2018 26.2 16.6 25 (1 092) 29.1 (551) 21.9 (502)
Denmark 2017 38.4 15.4 60.6 (3 109) 64.1 (1 540) 57.2 (1 482)
Germany 2018 28.2 16.9 57.9 (23 301) 68.3 (15 895) –
Estonia 2018 24.5 16.6 1 (3) 2.3 (2) 0.6 (1)
Ireland 2015 27.9 13.8 23 (2 276) 38 (1 503) 11.6 (637)
Greece 2015 11.0 4.5 28.1 (1 038) 47.7 (725) 14.6 (308)
Spain 2017 35.2 18.3 27.6 (12 932) 38.4 (9 122) 15.5 (3 314)
France 2017 44.8 21.8 59.8 (28 818) 74.4 (9 868) 42.9 (8 124)
Croatia 2015 19.4 16.0 – 62.9 (602) –
Italy 2017 32.7 20.9 22 (8 514) 32.4 (5 217) 14.6 (3 297)
Cyprus 2016 12.1 4.3 50.7 (566) 64.8 (351) 32 (155)
Latvia 2015 9.8 10.0 24 (194) 36 (154) 10.6 (40)
Lithuania 2016 10.8 6.0 5.1 (66) 19.3 (40) 2.2 (24)
Luxembourg 2014 23.3 9.8 25.8 (79) 39 (32) 21.2 (41)
Hungary 2015 7.4 3.5 67.4 (3 174) 72.4 (2 539) 48.9 (458)
Malta 2013 4.3 – 13.2 (251) 26.9 (105) 9.7 (146)
Netherlands 2018 28.6 17.1 47.3 (5 202) 55.5 (3 625) 35.4 (1 577)
Austria 2015 23.6 14.1 33 (1 367) 48.6 (895) 20.5 (472)
Poland 2018 12.1 7.8 31.5 (2 074) 39.5 (1 286) 23.2 (743)
Portugal 2016 11.0 8.0 40 (1 309) 53.7 (980) 22.8 (329)
Romania 2016 5.8 5.8 54.4 (2 320) 68.9 (2 003) 23.3 (317)
Slovenia 2018 20.7 12.3 6.8 (15) 26.5 (13) 1.2 (2)
Slovakia 2015 15.8 9.3 21.2 (643) 31.2 (384) 13.8 (235)
Finland 2018 25.6 15.5 18.3 (124) 32.2 (78) 10.6 (46)
Sweden (1) 2018 16.7 7.9 10.7 (4 537) 14.4 (2 029) 7.1 (1 875)
United Kingdom (2) 2018 29.0 13.4 22.4 (25 103) 42.7 (14 647) 13.4 (10 375)
Turkey 2017 2.7 1.8 8.3 (941) 12.9 (668) 4.4 (273)
Norway 2018 23.6 9.6 30.1 (1 795) 39.4 (1 071) 22.3 (724)
European Union – 27.2 15.0 32.4 (131 941) 46.8 (76 288) 17.5 (36 092)
EU, Turkey and Norway – – – 31.7 (134 677) 45.7 (78 027) 17.2 (37 089)
Prevalence estimates for the general population: United Kingdom estimates refer to England and Wales only. Age ranges are 18-64 and 18-34 for France,  
Germany, Greece and Hungary; 16-64 and 16-34 for Denmark, Estonia, Sweden, United Kingdom and Norway; 18-65 for Malta. 
Data on entrants into treatment are for 2018 or most recent year available: Estonia, 2016; Croatia, Latvia and Spain, 2017; Netherlands, 2015.
(1)  Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative  
of the national picture.
(2) Entrants into treatment do not include Northern Ireland.
Annex | National data tables 
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OTHER INDICATORS
TABLE A6
Country Year
Drug-induced deaths HIV 
diagnoses 
related to 
injecting drug 
use (ECDC)
Injecting drug use estimate Syringes 
distributed 
through 
specialised 
programmesAll ages Aged 15-64
Count
Cases per 
million 
population 
(count)
Cases per 
million 
population  
(count)
Year of 
estimate
Cases per 
1 000 
population
Count
Belgium 2014 61 8 (60) 1.1 (12) 2015 2.3-4.6 1 228 681
Bulgaria 2018 24 5 (21) 5.0 (35) – – 25 151
Czechia 2018 39 5 (36) 0.8 (8) 2018 5.8-6.0 6 932 269
Denmark 2017 238 52 (191) 1.0 (6) – – –
Germany (1) 2018 1 276 21 (1 120) 1.7 (140) – – –
Estonia 2018 39 43 (36) 18.2 (24) 2015 9.0-11.3 1 680 531
Ireland 2017 235 72 (227) 2.7 (13) – – 488 755
Greece 2017 62 – (–) 9.9 (106) 2018 0.4-0.7 245 860
Spain (2) 2017 437 14 (437) 1.6 (74) 2017 0.3-2.6 1 603 551
France (3) 2016 465 9 (391) 0.9 (61) 2017 2.6-3.3 11 998 221
Croatia (2) 2018 85 30 (80) 0.0 (0) 2015 1.8-2.9 244 299
Italy 2018 334 9 (332) 1.8 (106) – – –
Cyprus 2018 12 20 (12) 1.2 (1) 2018 0.4-0.8 243
Latvia 2018 20 16 (20) 37.7 (73) 2016 5.3-6.8 951 063
Lithuania 2018 59 32 (59) 19.6 (55) 2016 4.4-4.9 241 953
Luxembourg 2018 4 10 (4) 6.6 (4) 2015 3.8 492 704
Hungary 2018 33 4 (28) 0.1 (1) 2015 1.0 83 341
Malta 2017 5 16 (5) 0.0 (0) – – 275 969
Netherlands 2018 224 18 (206) 0.1 (2) 2015 0.07-0.09 –
Austria 2018 184 31 (184) 1.4 (12) – – 6 234 094
Poland 2017 202 7 (168) 0.5 (20) – – 129 681
Portugal 2017 51 6 (43) 2.0 (21) 2015 1.0-4.5 1 300 134
Romania (4) 2018 26 2 (26) 3.5 (68) – – 896 397
Slovenia 2018 59 41 (55) 0.0 (0) – – 591 080
Slovakia 2018 32 8 (30) 0.2 (1) – – 425 880
Finland 2018 261 72 (248) 1.1 (6) 2012 4.1-6.7 5 992 811
Sweden 2018 566 81 (515) 2.3 (23) – – 607 195
United Kingdom (5) 2017 3 284 76 (3 126) 1.4 (94) – – –
Turkey 2018 657 12 (637) 0.3 (24) – – –
Norway 2017 247 66 (229) 1.1 (6) 2017 2.0-2.6 3 000 000
European Union – 8 317 23.7 (7 660) 1.9 (966) – – –
EU, Turkey and Norway – 9 221 22.3 (8 526) 1.7 (996) – – –
In some cases, the age band is not specified, and these cases were not included in the calculations of mortality rate referring to the population aged 15-64:  
Portugal (1), Greece (62) and Turkey (14). 
(1) For ‘Drug-induced deaths (aged 15-64)’, the data for 2017 were used (147 cases without information on age). 
(2) Syringes distributed through specialised programmes refer to 2017.
(3) Syringes distributed through specialised programmes refer to 2016.
(4) Drug-induced deaths data with sub-national coverage: 3 counties out of 42 recorded DRD cases (Bucharest, Arad and Ilfov).
(5)  Drug-induced deaths data do not include Northern Ireland. Syringe data: England, no data; Wales 2 658 586; Scotland 4 401 387  
and Northern Ireland 337 390 both in 2017.
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TABLE A7
Country
Heroin Cocaine Amphetamines MDMA, MDA, MDEA
Quantity 
seized
Number 
of 
seizures
Quantity 
seized
Number 
of 
seizures
Quantity 
seized
Number 
of 
seizures
Quantity seized
Number 
of 
seizures
kg count kg count kg count tablets (kg) count
Belgium 4 537 1 762 53 032 5 646 75 3 109 225 908 (587) 2 462
Bulgaria 1 033 43 22 29 91 94 5 054 (320) 45
Czechia 1 110 24 297 108 2 053 32 591 (9) 577
Denmark 38 427 151 4 786 379 2 080 18 320 (4) 722
Germany 298 – 8 166 – 1 784 – 693 668 (–) –
Estonia <0.1 7 4 164 22 472 – (8) 275
Ireland – 313 – 608 – 90 – (–) 304
Greece 207 2 388 166 766 782 12 62 762 (5) 82
Spain 251 8 058 48 453 45 583 413 4 725 337 904 (293) 4 084
France 1 115 4 103 16 357 12 578 334 615 1 783 480 (–) 1 048
Croatia 5 146 109 455 37 981 – (12) 642
Italy 975 2 236 3 623 7 995 18 177 23 176 (21) 297
Cyprus <0.1 9 5 129 1 105 939 (0) 15
Latvia <0.1 40 5 91 55 487 14 967 (3) 352
Lithuania 3 157 14 99 43 318 – (17) 167
Luxembourg 3 75 347 215 1.9 11 1 564 (–) 20
Hungary 35 49 25 303 22 1 153 43 984 (1) 792
Malta 5 20 188 166 0.004 1 369 (0) 83
Netherlands (1) 354 – 40 134 – 7 – – (472) –
Austria 76 1 115 75 1 810 85 1 759 83 037 (12) 1 174
Poland 9 3 277 2 1 354 34 218 442 (408) –
Portugal 27 225 5 541 501 0.4 52 4 145 (19) 186
Romania 5 264 35 358 3 165 53 072 (1) 819
Slovenia 11 286 12 277 6 242 – (–) 63
Slovakia 0.6 41 1 32 4 661 – (–) 74
Finland 0.1 76 10 340 203 2 456 219 352 (–) 839
Sweden 75 780 544 3 995 1 052 6 974 147 792 (22) 2 171
United Kingdom 617 10 868 3 469 19 451 1 668 3 682 713 896 (1) 3 630
Turkey 18 531 18 298 1 509 3 519 6 273 15 528 8 409 892 (–) 9 758
Norway 50 781 98 1 862 418 6 711 60 400 (11) 1 366
European Union 9 681 36 610 180 787 110 196 8 549 46 349 4 684 422 (2 217) 24 443
EU, Turkey and Norway 28 262 55 689 182 394 115 577 15 240 68 588 13 154 714 (2 228) 35 567
All data are for 2018 or most recent year.
(1)  Data on number and quantity of seizures do not include all relevant law enforcement units and should be considered partial, minimum figures.  
Cocaine seizures represent the majority of large seizures.
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Country
Cannabis resin Herbal cannabis Cannabis plants
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures Quantity seized
Number of 
seizures
kg count kg count plants (kg) count
Belgium 108 6 889 17 290 28 801 422 261 (–) 1 006
Bulgaria 2 21 986 85 24 244 (108 509) 147
Czechia 3 189 948 5 779 28 334 (–) 441
Denmark 8 956 18 715 293 1 803 17 840 (272) 480
Germany 1 295 – 7 731 – 101 598 (–) –
Estonia 110 48 72 707 – (20) 40
Ireland – 176 – 1 352 – (–) 112
Greece 7 388 291 12 812 9 198 50 597 (–) 635
Spain 436 963 167 530 37 220 143 087 981 148 (–) 2 986
France 85 400 76 227 29 800 30 175 138 564 (–) 462
Croatia 50 326 4 687 7 388 3 614 (–) 132
Italy 78 522 9 661 39 178 10 432 430 277 (–) 1 262
Cyprus 1 28 319 997 301 (–) 21
Latvia 133 57 41 866 – (108) 46
Lithuania 389 75 168 606 – (–) –
Luxembourg 181 434 35 647 34 (–) 9
Hungary 20 164 868 3 492 4 769 (–) 167
Malta 17 366 22 594.6 171 2 (–) 2
Netherlands (1) 7 288 – 3 002 – 516 418 (–) –
Austria 111 1 077 1 382 16 029 24 571 (–) 565
Poland 8 316 26 4 260 149 118 781 (–) 10
Portugal 4 170 1 774 138 300 8 706 (–) 139
Romania 8 200 266 3 354 – (28) 87
Slovenia 20 107 838 3 768 13 594 (–) 218
Slovakia 1 26 144 1 115 2 299 (–) 31
Finland 54 280 344 1 040 13 085 (–) 1 073
Sweden 2 709 16 280 960 7 166 – (–) –
United Kingdom 8 470 11 876 29 533 101 744 372 207 (–) 8 382
Turkey 31 473 13 798 49 232 51 374 – (–) 2 812
Norway 2 658 6 771 354 3 908 – (–) –
European Union 668 032 318 273 193 909 411 873 3 273 244 (108 935) 20 660
EU, Turkey and Norway 702 163 338 842 243 495 467 155 3 273 244 (108 935) 23 472
All data are for 2018 or most recent year.
(1) Data on number and quantity of seizures do not include all relevant law enforcement units and should be considered partial, minimum figures. 
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European Drug Report: Trends and Developments
The Trends and Developments report, of which the Key 
Issues is a selected summary, presents a top-level overview 
of the drug phenomenon in Europe focused on illicit drug 
use, related health harms and drug supply. 
emcdda.europa.eu/edr2020
EMCDDA Publications 
In addition to the yearly European Drug Report, the EMCDDA 
publishes Health and Social Responses to Drug Use:  
A European Guide and, together with Europol, the European 
Drug Markets Report, alongside a wide range of detailed 
reports across the full spectrum of drugs issues. 
emcdda.europa.eu/publications
Best Practice
The Best Practice Portal provides practical and reliable 
information on what works (and what doesn't) in the 
areas of prevention, treatment, harm reduction and 
social reintegration. It will help you identify tried and 
tested interventions quickly, allocate resources to what's 
effective, and improve interventions applying tools, 
standards and guidelines.
emcdda.europa.eu/best-practice
Statistical Bulletin
The annual Statistical Bulletin contains the most recent 
available data on the drug situation in Europe provided 
by the Member States. These datasets underpin the 
analysis presented in the European Drug Report. All data 
may be viewed interactively on screen and downloaded 
in Excel format.
emcdda.europa.eu/data/
Topics
Hub pages and the A-Z index help you find EMCDDA  
content by topic. 
emcdda.europa.eu/topics
Document Library
The EMCDDA Document Library gives you access to 
documents related to the agency or collected by it in its 
work. There you can access publications by international and 
national organisations, scientific articles by EMCDDA staff, 
material published by other institutions of the European 
Union and other material acquired by the agency.
emcdda.europa.eu/document-library
EMCDDA 
RESOURCES
For in-depth information on illicit drugs consult 
EMCDDA publications and online resources.
 Getting in touch with the EU
In person
All over the European Union there are hundreds of Europe Direct 
information centres. You can  nd the address of the centre nearest you at: 
https://europa.eu/european-union/contact_en
On the phone or by email
Europe Direct is a service that answers your questions about the 
European Union. You can contact this service:
– by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for 
these calls),
– at the following standard number: +32 22999696 or
– by email via: https://europa.eu/european-union/contact_en
Finding information about the EU
Online
Information about the European Union in all the o  cial languages of the 
EU is available on the Europa website at: https://europa.eu/european-
union/index_en
EU publications
You can download or order free and priced EU publications at: 
https://publications.europa.eu/en/publications. Multiple copies of free 
publications may be obtained by contacting Europe Direct or your local 
information centre (see https://europa.eu/european-union/contact_en).
EU law and related documents
For access to legal information from the EU, including all EU law since 
1952 in all the o  cial language versions, go to EUR-Lex at: 
http://eur-lex.europa.eu
Open data from the EU
 e EU Open Data Portal (http://data.europa.eu/euodp/en) provides 
access to datasets from the EU. Data can be downloaded and reused for 
free, both for commercial and non-commercial purposes.
YEARS OF 
MONITORING 
1995–2020
About this report
The Key Issues of the 2020 European Drug Report 
presents a selection of the main findings from the 
EMCDDA’s latest analysis of the drug situation in 
Europe, chosen for their policy relevance and general 
interest. Illicit drug use, related harms and drug supply 
are the main focuses of the report, which also contains 
a comprehensive set of national data across these 
themes and key harm reduction interventions.
About the EMCDDA
 e European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
con rmed authority on drug-related issues in Europe. 
For 25 years, it has been collecting, analysing and 
disseminating scienti cally sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
 e EMCDDA’s publications are a prime source of 
information for a wide range of audiences including 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
